Fullerene-based inhibitors of HIV-1 protease

Abstract

A series of Fmoc-Phe(4-aza-C<inf>60</inf>)-OH of fullerene amino acid derived peptides have been prepared by solid phase peptide synthesis, in which the terminal amino acid, Phe(4-aza-C<inf>60</inf>)-OH, is derived from the dipolar addition to C<inf>60</inf> of the Fmoc-Nα-protected azido amino acids derived from phenylalanine: Fmoc-Phe(4-aza-C<inf>60</inf>)-Lys<inf>3</inf>-OH (1), Fmoc-Phe(4-aza-C<inf>60</inf>)-Pro-Hyp-Lys-OH (2), and Fmoc-Phe(4-aza-C<inf>60</inf>)-Hyp-Hyp-Lys-OH (3). The inhibition constant of our fullerene aspartic protease PRIs utilized FRET-based assay to evaluate the enzyme kinetics of HIV-1 PR at various concentrations of inhibitors. Simulation of the docking of the peptide Fmoc-Phe-Pro-Hyp-Lys-OH overestimated the inhibition, while the amino acid PRIs were well estimated. The experimental results show that C<inf>60</inf>-based amino acids are a good base structure in the design of protease inhibitors and that their inhibition can be improved upon by the addition of designer peptide sequences. © 2017 Elsevier B.V., All rights reserved.